Login to Your Account



Strong Data Has Trion, Fresenius Optimistic About Removab Filing

By Cormac Sheridan


Wednesday, July 25, 2007
Trion Pharma GmbH and its partner Fresenius Biotech GmbH remain on track to file for approval in Europe this year for their 'trifunctional antibody' removab (catumaxomab), which attained the primary endpoint and several secondary endpoints in a Phase II/III clinical trial in advanced cancer patients with malignant ascites. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription